Dyne Therapeutics (DYN) News Today → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free DYN Stock Alerts $28.75 -0.63 (-2.14%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 3:39 PM | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $29.38Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $29.38May 10, 2024 | americanbankingnews.comDyne Therapeutics, Inc. to Post FY2024 Earnings of ($2.87) Per Share, Chardan Capital Forecasts (NASDAQ:DYN)May 9, 2024 | marketbeat.comChardan Capital Weighs in on Dyne Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:DYN)Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Analysts at Chardan Capital issued their FY2024 earnings per share estimates for shares of Dyne Therapeutics in a research report issued on Monday, May 6th. Chardan Capital analyst K. Nakae expects that the company will earn ($2.87) per share fMay 9, 2024 | americanbankingnews.comChardan Capital Weighs in on Dyne Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:DYN)May 8, 2024 | marketbeat.comDyne Therapeutics, Inc. Expected to Earn FY2025 Earnings of ($2.94) Per Share (NASDAQ:DYN)Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Research analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for shares of Dyne Therapeutics in a report released on Monday, May 6th. Chardan Capital analyst K. Nakae forecasts that the company will post earningsMay 8, 2024 | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Stock Rating Reaffirmed by OppenheimerMay 8, 2024 | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Rating Reiterated by Chardan CapitalMay 7, 2024 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Dyne Therapeutics (NASDAQ:DYN)May 6, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Aldeyra Therapeutics (ALDX)May 6, 2024 | marketbeat.comDyne Therapeutics' (DYN) Outperform Rating Reaffirmed at OppenheimerOppenheimer reissued an "outperform" rating and issued a $47.00 target price on shares of Dyne Therapeutics in a report on Monday.May 6, 2024 | markets.businessinsider.comRobust Financial Health and Promising Clinical Trials Bolster Buy Rating for Dyne TherapeuticsMay 4, 2024 | finance.yahoo.comWe're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash WiselyMay 4, 2024 | finance.yahoo.comDyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns with Analyst ProjectionsMay 3, 2024 | finanznachrichten.deDyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 3, 2024 | msn.comDYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024May 2, 2024 | finance.yahoo.comDyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 2, 2024 | globenewswire.comDyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsApril 30, 2024 | msn.comMorgan Stanley Initiates Coverage of Dyne Therapeutics (DYN) with Overweight RecommendationApril 30, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Up to $25.46Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up to $25.46April 30, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Coverage Initiated at Morgan StanleyMorgan Stanley started coverage on shares of Dyne Therapeutics in a report on Tuesday. They set an "overweight" rating and a $40.00 price objective on the stock.April 27, 2024 | marketbeat.comVivo Capital LLC Has $46.42 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Vivo Capital LLC lifted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 58.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 1,635,136 shares of the company's stock after purchasing an additional 600,000 sharesApril 26, 2024 | marketbeat.comFederated Hermes Inc. Invests $4.99 Million in Dyne Therapeutics, Inc. (NASDAQ:DYN)Federated Hermes Inc. bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 375,000 shares of the company's stock, valued at approximately $4,988,0April 22, 2024 | finanznachrichten.deSynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCTApril 14, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Up 18.5% in MarchDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 8,080,000 shares, a growth of 18.5% from the March 15th total of 6,820,000 shares. Based on an average trading volume of 1,710,000 shares, the days-to-cover ratio is currently 4.7 days. Currently, 16.2% of the shares of the company are sold short.April 8, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)April 4, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Trading Down 3%Dyne Therapeutics (NASDAQ:DYN) Trading Down 3%April 2, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Assenagon Asset Management S.A.Assenagon Asset Management S.A. decreased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 60.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 286,644 shares of the companMarch 27, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Up 9.9%Dyne Therapeutics (NASDAQ:DYN) Stock Price Up 9.9%March 27, 2024 | globenewswire.comDyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive OfficerMarch 27, 2024 | globenewswire.comDyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy SymposiumMarch 26, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Dyne Therapeutics (DYN), Addus Homecare (ADUS)March 26, 2024 | marketbeat.comOppenheimer Reiterates "Outperform" Rating for Dyne Therapeutics (NASDAQ:DYN)Oppenheimer reaffirmed an "outperform" rating and set a $47.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday.March 25, 2024 | bizjournals.comDyne announces CEO transition, former Biogen exec tapped for top spotMarch 25, 2024 | marketwatch.comDyne Therapeutics Shares Drop 14% on CEO Joshua Brumm DepartureMarch 25, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $28.24Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $28.24March 25, 2024 | finanznachrichten.deDyne Therapeutics, Inc.: Dyne Therapeutics Announces CEO TransitionMarch 25, 2024 | markets.businessinsider.comDyne Therapeutics Appoints John Cox As CEO To Succeed Joshua BrummMarch 25, 2024 | marketwatch.comDyne Therapeutics CEO Joshua Brumm to Exit For Investing CareerMarch 25, 2024 | globenewswire.comDyne Therapeutics Announces CEO TransitionMarch 20, 2024 | fool.comDyne Therapeutics (NASDAQ: DYN)March 19, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest UpdateDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) was the target of a significant decrease in short interest in the month of February. As of February 29th, there was short interest totalling 6,610,000 shares, a decrease of 8.8% from the February 14th total of 7,250,000 shares. Based on an average daily volume of 1,980,000 shares, the short-interest ratio is currently 3.3 days. Approximately 16.6% of the company's shares are sold short.March 18, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.4%Dyne Therapeutics (NASDAQ:DYN) Shares Down 4.4%March 18, 2024 | finance.yahoo.comDYN Apr 2024 30.000 putMarch 17, 2024 | marketbeat.comWalleye Capital LLC Takes $2.51 Million Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Walleye Capital LLC acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 280,276 shares of the company's stock, valued at approxiMarch 16, 2024 | finance.yahoo.comDYN Apr 2024 22.500 callMarch 16, 2024 | ca.finance.yahoo.comDYN Apr 2024 30.000 callMarch 14, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Vida Ventures Advisors LLCVida Ventures Advisors LLC cut its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 6.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,074,787 shares of the company's stock after selling 145,March 14, 2024 | markets.businessinsider.comNeuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock SurgeMarch 14, 2024 | insidertrades.comDyne Therapeutics, Inc. (NASDAQ:DYN) COO Sells $58,904.40 in StockMarch 13, 2024 | globenewswire.comDyne Therapeutics to Present at Stifel 2024 Virtual CNS Days Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking $16T Elon Musk Crypto Leak (Ad)There’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening. Click here for all the details… DYN Media Mentions By Week DYN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DYN News Sentiment▼0.970.55▲Average Medical News Sentiment DYN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DYN Articles This Week▼73▲DYN Articles Average Week Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PTC Therapeutics News Today Bausch Health Companies News Today MoonLake Immunotherapeutics News Today ACADIA Pharmaceuticals News Today Merus News Today Janux Therapeutics News Today Indivior News Today Rhythm Pharmaceuticals News Today TG Therapeutics News Today MorphoSys News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DYN) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe 1,000X Crypto PlaybookTrue Market InsidersCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMost important medical advance in 100 yearsThe Oxford ClubBill Clinton Backing Biden Replacement???The Freeport SocietyCharles Payne Demystifies OptionsUnstoppable ProsperityWhy Is Gold On a MASSIVE rally? Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
